<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82282">
  <stage>Registered</stage>
  <submitdate>12/09/2007</submitdate>
  <approvaldate>26/08/2008</approvaldate>
  <actrnumber>ACTRN12608000429358</actrnumber>
  <trial_identification>
    <studytitle>A Phase II open-label pilot study to assess the effects of Testosterone Metered Dose Transdermal System (MDTS) administration on cognitive function in women</studytitle>
    <scientifictitle>A Phase II open-label pilot study to assess the effects of Testosterone Metered Dose Transdermal System (MDTS) administration on cognitive function in women</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>cognition</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>administration of 180microlitres transdermal testosterone spray daily for 26 weeks</interventions>
    <comparator>nil</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>effects on cognition as measured by functional MRI (magnetic resonance imaging)</outcome>
      <timepoint>0 weeks and 26 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>effects on cognition as measured by CogState and pre-pulse inhibition testing</outcome>
      <timepoint>screening, 0, 12 and 26 weeks for CogState; 0 and 26 weeks for prepulse inhibition testing</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy postmenopausal women on stable non-oral oestrogen for at least 8 weeks</inclusivecriteria>
    <inclusiveminage>45</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>history of cancer exluding non-melanotic skin cancer, significant heart, liver, kidney, endocrine disease or neurological disease, androgenic alopecia, current androgen or anti-androgen therapy, epilepsy, seizures, psychiatric illness,  previous neurological or head injury, intellectual disability, uncontrolled hypertension, recent major gynaecological surgery, total tesosterone levels higher than the upper limit of the normal reference range for young premenopausal women, alcohol consumption of greater than 3 standard drinks per day, if uterus in situ use of progestin other than Mirena intra-uterine device, presence of implanted metallic material or devices, severe claustrophobia</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment>allocation is not concealed</concealment>
    <sequence>not applicable</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>18/09/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>10</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3181</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>FemPharm Pty Ltd</primarysponsorname>
    <primarysponsoraddress>103-113 Stanley Street
West Melbourne VIC 3003</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>GPO Box 1421
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Charities/Societies/Foundations</sponsortype>
      <sponsorname>Royal Australasian College of Physicians Research and Education Foundation</sponsorname>
      <sponsoraddress>Macquarie Street
Sydney NSW 2000</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>University</othercollaboratortype>
      <othercollaboratorname>Howard Florey Institute</othercollaboratorname>
      <othercollaboratoraddress>University of Melbourne
Parkville VIC 3010</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A 26 week study to assess the effects of transdermal testosterone spray on cognitive function in healthy postmenopausal women aged 45-60 years.</summary>
    <trialwebsite>http://womenshealth.med.monash.edu.au</trialwebsite>
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Alfred Hospital Ethics Committee</ethicname>
      <ethicaddress>The Alfred Hospital
Commercial Road
Prahran VIC 3181</ethicaddress>
      <ethicapprovaldate>4/09/2007</ethicapprovaldate>
      <hrec>125/07</hrec>
      <ethicsubmitdate>28/05/2007</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sonia Davison</name>
      <address>Women's Health Program,
Department of Medicine,
Monash Medical School,
Alfred Hospital,
Commercial Road
Prahran VIC 3181</address>
      <phone>03 9903 0827</phone>
      <fax>03 9903 0828</fax>
      <email>womens.health@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sonia Davison</name>
      <address>Women's Health Program,
Department of Medicine,
Monash Medical School,
Alfred Hospital,
Commercial Road
Prahran VIC 3181</address>
      <phone>03 9903 0827</phone>
      <fax>03 9903 0828</fax>
      <email>womens.health@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Sonia Davison</name>
      <address>Women's Health Program,
Department of Medicine,
Monash Medical School,
Alfred Hospital,
Commercial Road
Prahran VIC 3181</address>
      <phone>03 9903 0827</phone>
      <fax>03 9903 0828</fax>
      <email>womens.health@med.monash.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>